Pharmacogenomic study on anti-VEGF medicine in treatment of macular Neovascular diseases: a study protocol for a prospective observational study.

BMC Ophthalmol 2018 Jul 24;18(1):181. Epub 2018 Jul 24.

Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, People's Republic of China.

Background: Macular neovascular diseases can cause severe vision loss. A newly approved anti-VEGF drug Conbercept has shown good efficacy and safety in rigorous random controlled trials (RCT), however, it cannot fully reflect the clinical application of Conbercept in real world clinical practice. Moreover, anti-VEGF drugs are expensive and often require multiple treatments, and some patients have poor or even no response to the drugs,this resulted enormous waste of medical resources. Therefore, how to find out those patients who have good response, and how to develop individualized therapeutic regimen in real world need to be urgently investigated in the aspect of pharmacogenomics and pharmacometabolomics.

Methods: This study is a multicenter, prospective, observational study of Conbecept treating macular neovascular diseases in China. Patients suffered from age-related macular degeneration, polypoidal choroidal vasculopathy, and pathological myopia who already planned to receive Conbercept treatment will be recruited. We aimed to enroll more than 5000 patients from 43 ophthalmic centers in China. Patients' clinical data and blood samples will be collected during the one-year follow-up period. Finally, the safety and efficacy of Conbercept, and the potential predictors of patients' response to Conbercept will be investigated by pharmacogenomics and pharmacometabolomics analysis.

Discussion: This study will provide important data of Conbercept in treating macular neovascular diseases in real world. Besides, finding the predictor of patients' response will help doctor make more precise individualized therapeutic regimens.

Trial Registration: ClinicalTrials.gov, NCT03128463 . Registered on 9 March 2017.

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12886-018-0812-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057085PMC

Still can't find the full text of the article?

We can help you send a request to the authors directly.
July 2018
11 Reads

Publication Analysis

Top Keywords

macular neovascular
16
neovascular diseases
16
individualized therapeutic
8
prospective observational
8
patients' response
8
observational study
8
treating macular
8
conbercept
6
will
5
study
5
macular
5
ophthalmic centers
4
pathological myopia
4
patients ophthalmic
4
centers china
4
choroidal vasculopathy
4
degeneration polypoidal
4
polypoidal choroidal
4
5000 patients
4
vasculopathy pathological
4

References

(Supplied by CrossRef)
Article in ProgRetin Eye Res
CW Wong et al.
ProgRetin Eye Res 2016
Article in Ophthalmic Epidemiol
H Hashemi et al.
Ophthalmic Epidemiol 2017
Article in Arch Ophthalmol
DS Friedman et al.
Arch Ophthalmol 2004
Article in Eye Contact Lens
NS Chan et al.
Eye Contact Lens 2016
Article in Eur J Ophthalmol
C Giuffrè et al.
Eur J Ophthalmol 2017
Article in Int J Ophthalmol
Y Tong et al.
Int J Ophthalmol 2016
Article in Drugs
KYC Teo et al.
Drugs 2016
Article in Pharm Res
M Zhang et al.
Pharm Res 2009
Article in Ophthalmology
M Zhang et al.
Ophthalmology 2011
Article in Retina
J Qu et al.
Retina 2016

Similar Publications